FARON Stock Overview
Operates as a clinical stage drug discovery and development company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.14 |
| 52 Week High | UK£4.59 |
| 52 Week Low | UK£1.05 |
| Beta | 0.18 |
| 11 Month Change | -49.56% |
| 3 Month Change | -32.94% |
| 1 Year Change | -61.22% |
| 33 Year Change | -75.00% |
| 5 Year Change | n/a |
| Change since IPO | -67.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| FARON | FI Biotechs | FI Market | |
|---|---|---|---|
| 7D | -2.6% | 1.7% | 1.1% |
| 1Y | -61.2% | -7.9% | -6.0% |
Return vs Industry: FARON underperformed the Finnish Biotechs industry which returned -7.9% over the past year.
Return vs Market: FARON underperformed the Finnish Market which returned -6% over the past year.
Price Volatility
| FARON volatility | |
|---|---|
| FARON Average Weekly Movement | 20.4% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FI Market | 8.4% |
| 10% least volatile stocks in FI Market | 3.0% |
Stable Share Price: FARON's share price has been volatile over the past 3 months.
Volatility Over Time: FARON's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
| FARON fundamental statistics | |
|---|---|
| Market cap | €83.87m |
| Earnings (TTM) | -€30.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs FARON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FARON income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €30.94m |
| Earnings | -€30.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -85.1% |
How did FARON perform over the long term?
See historical performance and comparison